Engineering the next computational and therapeutic paradigm.
Foundational platforms across biological computation, advanced therapeutic delivery, and direct neural interface.
We design the foundational layer of what comes next — the substrate beneath next-generation computation, the architecture beneath the next class of medicines, and the interface between human cognition and machine intelligence.
Foundational, not incremental.
We build the layer below the application — the platform that everything downstream depends on.
Independent, by design.
Architected outside legacy supply chains and academic capture — portable, transferable, owned end-to-end.
Long-horizon.
Engineered for the next two decades of compute, medicine, and cognition — not the next quarter.
Three foundational platforms, one underlying thesis.
Each platform is built to be the substrate layer beneath an entire industry — independently transformative, collectively unprecedented.
Biological Computation
Compute beyond silicon.
A new class of computing infrastructure built from living systems — orders of magnitude more energy-efficient than conventional silicon and independent of legacy fabrication supply chains. Designed to anchor the post-silicon era of AI compute.
Therapeutic Delivery
Medicine reimagined.
Programmable delivery platforms that move advanced therapeutics across biological barriers and into the right cell at the right time. Spanning small molecules through gene editing and engineered cellular agents.
Neural Interface
Cognition, augmented.
Architectures that bridge biological neural systems and computational substrates — designed for clinical neurology, cognitive enhancement, and the long arc of human–machine integration.
For inquiries, three primary tracks.
Industry partnership.
Licensing and co-development with pharmaceutical and technology operators building at the frontier.
Federal alignment.
Engagement with federal research and defense programs aligned to national strategic technology priorities.
Philanthropic.
Partnerships with disease foundations and patient-access organizations advancing equitable therapeutic deployment.
Direct correspondence preferred. Standard inquiries are reviewed within five business days.